ADMINISTRATIVE, MANAGEMENT AND SUPERVISORY BODIES AND SENIOR MANAGEMENT 14 the biotech industry and drug development space for many years, acquisition by BioMarin Falcon B.V. in December 2014. Mr. served as Chief Executive Officer of Danube Pharmaceuticals Wyzga received an M.B.A. from Providence College and a B.S. Inc., Chief Medical Officer of Fovea Pharmaceuticals, and Vice from Suffolk University. President for Medical Affairs and Strategy at Eyetech [Group Ltd.]. He studied at the National Hospital for Nervous Disease at Peter Goodfellow, Ph.D. has served as a director since June 2014. Queen’s Square in London, and served fellowships at Harvard and Dr. Goodfellow is a scientific consultant for Abingworth, Sanofi the University of California San Francisco. He interned in Internal and the Bil l and Melinda Gates Foundation. Dr. Goodfel low Medicine at Parkland Hospital in Dal las, went to the National was previously the Balfour Professor of Genetics at Cambridge Institutes of Health in Neuro-Virology, completed a Neurology University before working for SmithKline Beecham (later residency at Harvard Medical School and an Ophthalmology GlaxoSmithKline) as head of research. He has founded several residency at Tufts-New England Medical Center. Dr. Katz biotechnology companies and has sat on the boards of Prosensa received his M.D. from Case-Western Reserve University deCode and several medical charities. Dr. Goodfellow currently School of Medicine after graduating from Colgate University, serves as the chairman of the Board of Directors of GammaDelta and obtained an MBA from the University of Rochester’s Simon Therapeutics, a biotech developing novel immunotherapies for School of Business. cancer and other diseases. Dr. Goodfellow holds doctorates from Oxford and Bristol Universities. Directors Guido Magni, M.D.,Ph.D. has served as a director since MichaelWyzga has served as a director since October 2013 March 2013. Dr. Magni has been a Partner with Versant Ventures, and as ourChairman since March2016. M r.Wyzga si based in Basel, Switzerland. Since 2012, Dr. Magni has served currently the President of MSW Consulting, Inc., a private as a Managing Director of EuroVentures, a Versant incubator, company focused on strategic biotechnology consulting. Prior where he was involved with several biotech investments including to that, Mr. Wyzga served as President and Chief Executive Synosia Therapeutics AG, which was sold to Biotie Therapeutics Officer and a member of the Board of Directors of Radius AG, Flexion Therapeutics Inc. and Okairos AG, which was sold to Health, Inc. (Nasdaq: RDUS), a biopharmaceutical company, GlaxoSmithKline. Dr Magni was also the Chief Medical Officer of from December 2011 until November 2013. Prior to that, River Vision, which was sold to Horizon Pharma in 2017. Dr. Magni Mr. Wyzga served in various senior management positions at was previously the Global Head of Medical Sciences of Roche Genzyme Corporation, a biopharmaceutical company, which Pharmaceuticals, in the Global Drug Development department. was acquired by Sanofi in 2011. Mr. Wyzga joined Genzyme During his twelve years in this position, Dr. Magni oversaw the in February 1998 and most recently served as Executive Vice development and the registration of a large number of new President, Finance from May 2003 until November 2011 and chemical and biological entities including Pegasys, Mabthera, as Chief Financial Officer from July 1999 until November 2011. Xeloda, Herceptin, Tamiflu and Tarceva. Dr. Magni currently Since February 2014, Mr. Wyzga has served as a member of the serves on the boards of Aprea AB, Nouscom GmbH, Piqur Board of Directors of Akebia Therapeutics, Inc. (Nasdaq: AKBA), Therapeutics AG, Tarveda, LavaTherapeutics and AM Pharma a biopharmaceutical company, where he is also a member of the B.V. Dr. Magni holds an M.D. and a Ph.D. in neuropharmacology compensation committee and chair of the audit committee. Since from the University of Padua in Italy. February 2013, Mr. Wyzga has also served as a member of the Simone Seiter, M.D., Ph.D. has served as a director since Board of Directors and chair of the audit committee of OncoMed April 2017. Dr. Seiter is a Vice President with IQVIA (formerly Pharmaceuticals, Inc. (Nasdaq: OMED) a biopharmaceutical QuintilesIMS) based in Frankfurt, Germany and has held company. Since February2015, Mr. Wyzga has also served as a the role for 12 years. Prior to joining QuintilesIMS she member of the Board of Directors of Exact Sciences Corporation worked at Capgemini as a consultant for six years and served (Nasdaq: EXAS), a medical technology company, where he is also as a postdoctoral Fel low at the National Institutes of Health a member of the audit and compensation committees. Mr. Wyzga (United States) for two years. Previously, Dr. Seiter worked also previously served as a member of the Board of Directors at the Universities of Heidelberg and Homburg, Germany as of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology board certified dermatologist. Dr. Seiter holds an M.D. Ph.D. company that was acquired by Merck in August 2014, were heh degree from the University of Heidelberg and an MBA from the also served as the chair of the audit committee and a member University of Applied Sciences in Neu-Ulm Germany. of the compensation committee, Altus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company that ceased Natalie Mount, Ph.D. has served as a director since May 2017. operations in November2009, and as a member of the supervisory Dr. Mount is currently Chief Scientific Officer, leading Research board of Prosensa Holding B.V., or Prosensa, a publicly traded and Development activities at GammaDelta Therapeutics. biopharmaceutical company, from June 2014 until the Prosensa Previously, she was Chief Clinical Officer at the Cell and Gene GENSIGHT BIOLOGICS – 2017 Registration Document– 149